Influence of OATP1B1 and BRCP Genotype on Rosuvastatin PK, PD and Lipidomics in Hyperlipidemic Patients

Inclusion Criteria: * Adults aged 35 to 55 years at the time of screening * Serum LDL cholesterol (LDL-C) level ≤130 mg/dL * Must be reliable and willing to make themselves available during the study period * Must be willing to give blood sample for genotyping Exclusion Criteria: * A subject with present clinical manifestation or past medical history of hepatic, renal, respiratory, neurologic, hematologic, oncologic, psychiatric, cardiovascular or endocrine disease, except hyperlipidemia and mild hypertension (SBP \< 160 mmg, DBP \<100 mmHg). * Administration of lipid lowering agent within 2 weeks before the first study drug administration. * A subject with a history of gastrointestinal disease or surgery (except simple appendectomy or repair of hernia), which could influence the absorption of the study drug. * A subject with a history of drug abuse, or a positive urine drug screening test * A subject who takes or should take any medication that can influence lipid lowering effects or metabolic profiles of the study drug during the study period. (Investigators judge the wash-out period of the previously used medication before the administration of the study drug.) * A subject who has participated in any other clinical trial within 3 months before the study drug administration. * A subject who is judged to be ineligible to participate in the study due to abnormal clinical laboratory results or other reasons by investigators.